Introduction
The current therapies for autoimmune diseases, including multiple sclerosis (MS), are often unsuccessful in stopping or reversing disease progression and may lead to non-specific immunosuppression [1, 2] . Effective antigen-specific immunotherapy (ASIT) has the potential to suppress the immune response in regard to a specific autoantigen, and therefore would not hinder the ability of the patient's immune system to fight off foreign pathogens. Unfortunately, attempts to create ASIT for autoimmunity using only autoantigen have largely been unsuccessful [3] [4] [5] . In recent years, the idea of combining autoantigen and immunomodulators has emerged as a way to improve upon ASIT for autoimmunity [6] . Promising research has indicated that co-delivery of a small molecule immunomodulator with an autoantigen can lead to the creation of antigen-specific treatment of autoimmune disease [7] [8] [9] [10] [11] .
Co-delivery of autoantigen and immunomodulator has been successful in animal models of autoimmunity [7] [8] [9] [10] [11] [12] [13] [14] . These promising results may be attributed to the spatial and temporal combination of the components in order to elicit the appropriate antigen-specific immune response. In fact, traditional vaccines have utilized co-delivery of antigen and immunomodulator (i.e., adjuvant) to successfully induce a protective antigen-specific response [15] . One hypothesized mechanism for the success of co-delivery is the ability to mimic the natural twosignal paradigm of antigen-specific immunity, wherein concurrent antigen and secondary signal (co-stimulatory or co-inhibitory) are needed to elicit an antigen-specific immune response [15, 16] . In this regard, several studies have explored co-delivery of autoantigen and immunomodulator that allow for the controlled release of one or both components, increasing the exposure of immune cells to antigen and/or immunomodulator, which is known to contribute to efficacy of antigenspecific responses in autoimmune models [7] [8] [9] [10] [11] 15] .
The potential to mimic vaccine mechanisms, not only through antigen and adjuvant co-delivery but also through induction of humoral and/or T-helper type-2 (Th2) immunity, has shown efficacy in the treatment of T-helper type-1 (Th1) related autoimmune diseases. Both MS and the murine model of the disease, experimental autoimmune encephalomyelitis (EAE), are believed to be primarily Th1 and T-helper type-17 (Th17)-mediated [17, 18] . Utilizing an adjuvant initially developed for protective vaccination against foreign pathogens, incomplete Freund's adjuvant (IFA), studies have shown a shift from an autoantigen-specific Th1/Th17 towards a Th2/humoral response resulting in the suppression of autoimmune disease in animals [19, 20] .
IFA is composed of 85% mineral oil (paraffin oil) and 15% emulsifier (mannide monooleate), and forms a water-in-oil emulsion when combined with an aqueous phase [21] . A 1:1 emulsion of IFA with an aqueous solution containing antigen has been shown to enhance the antigen-specific immune response in animals [16, [21] [22] [23] . Additionally, IFA emulsions both alone and in combination with autoantigen have demonstrated the capacity to mitigate symptoms of autoimmune disease [19, 20, [24] [25] [26] [27] [28] [29] . A recent clinical trial has also shown the ability of IFA to deliver autoantigen for the treatment of type 1 diabetes in humans [30] .
Recently our lab has found that co-delivery of dexamethasone (DEX) and a disease-specific autoantigen was able to suppress inflammation in EAE splenocytes ex vivo [31] . Although traditionally thought of as a general immunosuppressant, DEX has been shown to be an effective immunomodulator with the ability to decrease the Th1 response, enhance the Th2 response, and even skew the immune system towards a regulatory response [32] [33] [34] [35] [36] . Our lab has verified these results in a screen of eleven immunomodulators in antigen-specific splenocytes obtained from EAE mice, and determined that DEX was capable of suppressing pro-inflammatory Th1-related cytokines, increasing regulatory cytokines, and decreasing the overall T-cell response [31] . Other groups have tested the co-administration or co-delivery of DEX and autoantigen in animal models of autoimmunity with successful outcomes [9, 37] .
In this manuscript, we investigated the co-delivery of DEX and proteolipid protein epitope (PLP 139-151 ), the antigen used to induce EAE, via an IFA emulsion. Additionally, all individual components of the co-delivery system and their possible combinations were investigated for the treatment of EAE. To our knowledge, this is the first study demonstrating the use of IFA for co-delivery of an immunomodulator and autoantigen for autoimmune therapy. Our approach seeks to expand upon current knowledge of co-delivery in ASIT immunotherapy, the unique immune effects of IFA, and the immunomodulatory mechanisms of DEX in order to create an antigenspecific therapy for autoimmunity.
Materials and methods

Materials
The peptide antigen, PLP 139-151 (PLP), was obtained from PolyPeptide Laboratories (Torrance, CA). For EAE induction incomplete Freund's adjuvant (IFA) and killed Mycobacterium tuberculosis strain H37RA were purchased from Difco (Sparks, MD), and pertussis toxin was purchased from List Biological Laboratories (Campbell, CA). Dexamethasone (DEX) was purchased from Sigma-Aldrich (St. Louis, MO). For flow cytometry studies, Alexa Fluor® 488-conjugated antimouse CD3, Alexa Fluor® 647-conjugated anti-mouse CD19, and Pacific Blue™-conjugated anti-mouse CD11c, and their respective isotype controls were purchased from Biolegend (San Diego, CA). All other chemicals and reagents were analytical grade and used as received.
Preparation of IFA emulsion
All IFA emulsions were created with a 1:1 volumetric ratio of IFA to phosphate buffered saline (PBS), unless otherwise noted. Before emulsification of peptide-containing emulsions, PLP was solubilized in PBS at 2× the final concentration of 2000 μM. For formulations including DEX, DEX was first dissolved in DMSO and added to the PBS phase before emulsification such that the final amount of DMSO was < 0.5% (the maximum concentration recommended by ICH Guideline, Impurities: Guideline for Residual Solvents, Q3C (R5), 2011) and the final concentration of DEX was 20 μg/mL. The IFA and PBS phases were then emulsified using a 20 gauge micro-emulsifying needle (stainless steel, 20G × 2-7/8″ with reinforcing bar, Cadence Science, Inc.) using two 6 cm 3 plastic syringes, and the emulsion was passed through the needle 15 times. For in vivo treatments, IFA emulsions were vortexed (speed 10, Mini Vortexer, Fisher Scientific) for 3 min immediately prior to injection.
Characterization of IFA emulsions
To characterize properties of the IFA emulsions, Nile Blue A (Sigma Aldrich) was dissolved in ethanol and introduced to IFA oil (10 μM final dye concentration, < 0.5% residual ethanol). The dye-containing oil was sonicated for 5 min to disintegrate Nile Blue particles, then emulsified with PBS and vortexed as described above. 5 μL of the IFA emulsion was inserted to an uncoated μ-Slide Chemotaxis (ibidi), and sample insertion ports were blocked to immobilize the emulsion. The slide was imaged using an Olympus IX-81 with ZDC (Olympus Scientific Solutions Americas, Waltham, MA) scope configured with a Prior H117 with Proscan III stage (Prior Scientific Inc., Rockland, MA), Hamamatsu ORCA-R2 CCD camera (Hamamatsu Corporation, Bridgewater, NJ), Sutter Lambda 10-3 filter wheel and Lambda LS Xenon light source (Sutter Instrument, Novato, CA), and Olympus Objectives -10 × 0.3NA, 20 × 0.5NA, 40 × 0.6NA, 60 × 0.7NA (Olympus Scientific Solutions Americas, Waltham, MA). Nile Blue A fluorescence (excitation 631 nm/emission 660 nm) was captured with filters 560 nm ± 25, 607 nm ± 36, 650 nm ± 13, and 684 nm ± 24. Images were acquired and analyzed using SlideBook 6.0 (Intelligent Imaging Innovations, Denver, CO). Stability was also investigated for IFA emulsions by monitoring the formulations hourly for phase separation and photographically documenting the emulsion integrity.
Characterization of PLP and DEX release
For the release characterization, 4 mL of the IFA emulsion was placed into regenerated cellulose dialysis bags with 6000-8000 MWCO (30 μm wall thickness, Fisherbrand Dialysis Tubing) which was then placed into 100 mL of PBS in a glass beaker covered using parafilm. Alternatively, PLP and DEX were also placed in PBS at the same concentration as in the final emulsion, and release was characterized via the same procedure. All release studies were kept at 37°C on an incubator shaker (79 rpm, Excella E24 Incubator Shaker, New Brunswick Scientific), and 1 mL samples were taken from the outermost PBS phase at specific time points; with 1 mL of PBS added for media replacement at each time point. Characterization of the PLP and DEX concentrations released from the dialysis bags were performed using gradient reversephase HPLC (Waters 2796 Bioseparations Module, Waters Corp) on a C 4 analytical column (Waters XBridge Protein BEH column, 300 Å, 3.5 μm, 4.6 mm × 150 mm, 10-500 K). Samples were eluted using mobile phases A (100% water with 0.1% trifluoroacetic acid (TFA)) and B (100% acetonitrile with 0.1% TFA) with a linear gradient of 100% A to 20% A over 25 min at a constant flow of 1 mL/min. PLP was detected at 220 nm and DEX was detected at 240 nm with a dual wavelength absorbance detector (Waters 2487 Dual λ Absorbance Detector, Waters Corp). Data was collected and processed using Empower 3 Software (Waters Corp).
Induction of EAE and therapeutic study
SJL/J female mice, 4-5 weeks old, were purchased from Envigo Laboratories and housed under specified, pathogen-free conditions at The University of Kansas. All protocols involving live mice were approved by The University of Kansas Institutional Animal Care and Use Committee. Mice were immunized subcutaneously with 200 μg of PLP in a 0.2 mL emulsion of Complete Freund's Adjuvant (CFA), composed of equal volumes of PBS and IFA also containing killed Mycobacterium tuberculosis strain H37RA at a final concentration of 4 mg/mL. The CFA containing PLP was administered to regions above the shoulders and the flanks (total of four sites; 50 μL at each injection site). In addition, 100 μL of pertussis toxin (200 ng) was injected intraperitoneally on the day of immunization (day 0) and 2 days post-immunization. Each treatment group contained six mice, except for the group with PLP treatment, which only contained five mice due to an unexpected death before disease induction. Mice received 100 μL subcutaneous injections of treatment at the nape of the neck on days 4, 7, and 10 of the study. All DEX-containing treatment groups were given at 20 μg DEX per injection and all PLP-containing treatments groups were given on a 200 nmol PLP per injection basis. All IFA emulsions were administered within 30 min of fabrication. Disease progression was evaluated using clinical scoring as follows: 0, no clinical signs of the disease; 1, tail weakness or limp tail; 2, paraparesis (weakness or incomplete paralysis of one or two hind limbs); 3, paraplegia (complete paralysis of two hind limbs); 4, paraplegia with forelimb weakness or paralysis; and 5, moribund. Body weight was also measured daily.
Splenocyte isolation and ex vivo treatment
Mouse spleens were resected from EAE mice on day 25 following disease-induction and cultured as previously described [13] . Briefly, the spleens were first passed through a wire mesh using the rubber end of a sterile 1 mL syringe plunger, and collected in 5 mL of RPMI 1640 media. The crude cellular extract was then centrifuged and the resulting cell pellet was resuspended in 3.5 mL of 1× Gey's lysis solution and placed on ice for 3.5 min to lyse splenic red blood cells. The lysis reaction was stopped by the addition of 10 mL RPMI 1640 media containing 10% FBS and centrifuged at 1100 ×g for 5 min. The remaining cell pellet was resuspended in fresh media (RPMI 1640 media containing 10% FBS and 1% Penicillin-Streptomycin) and seeded in 96-well cell culture plates at a cell density of 1 × 10 6 cells/well in a final volume of 200 μL. The cells were immediately rechallenged with and without 25 μM PLP antigen. Stimulated cell cultures were incubated for 120 h at 37°C in a CO 2 (5%) incubator.
Measurement of cytokines
Supernatants of cell cultures were collected after a120 hour incubation period following the day 25 spleen harvest. Secreted cytokines; GM-CSF, TNF-α, IL-2, IFN-γ, IL-10, IL-17, IL-15, and IL-23 were detected using a U-Plex assay kit according to manufacturer instructions (Meso Scale Discovery). Briefly, each U-Plex was coated with 50 μL of the multiplex coating solution containing linker and biotinylated capture antibody combinations for each cytokine and incubated on a shaker at 700 rpm for 1 h at room temperature. Following washing each well 3 times with 150 μL PBS containing 0.05% Tween 20, 25 μL of diluent and 25 μL of sample was added to each well and incubated again for 1 h on a shaker at room temperature. Detection antibody was added at 50 μL/well and incubated for 1 h. Finally, each assay plate was read using the QuickPlex multiplex plate reader (Meso Scale Discovery).
Measurement of cellular metabolism
Cell metabolism was determined by a resazurin (7-hydroxy-3H-phenoxazin-3-one 10-oxide) assay. Briefly, resazurin (75 μmol/L final) was added to splenocyte cultures and incubated for 3 h. Metabolic reductive capacity was determined by a change in fluorescence (excitation 560 nm/emission 590 nm). Background fluorescence was determined in RPMI media and was subtracted from each experimental read. All fluorescent readings were performed using a Spectramax M5 (Molecular Devices) plate reader.
Fluorescent staining and flow cytometry
Immediately after isolation, splenocytes were seeded in 12-well cell culture plates at a cell density of 5 × 10 6 cells/well in a final volume of 1.5 mL. Treatments were then given at the concentration of interest, both with and without 25 μM PLP. Cell cultures were then incubated for 120 h at 37°C in a CO 2 (5%) incubator. At 120 h, splenocytes were stained with the desired antibodies. Briefly, 1 × 10 6 cells were washed with 1 mL of wash buffer (RPMI 1640 media containing 5% FBS) before centrifugation and resuspension in 50 μL block buffer containing 20 μg/ mL TruStain fcX (anti-mouse CD16/32 antibody, Biolegend) in wash buffer. Cells were incubated on ice for 25 min before adding the desired antibodies or isotype controls in 50 μL at 2× the manufacturer recommended concentration for 1 h. For flow cytometry analysis, 40,000 cells per sample were detected using a BD FACSFusion cytometer. Data was analyzed using FlowJo Software.
Detection of PLP-specific antibody-secreting cells by ELISpot
96-well plates (Immunlon 2HB) were coated with 50 μg/mL PLP in 100 μL of PBS and incubated overnight at 4°C. The PLP coating solution was discarded and the plate was blocked with PBS containing 0.5% FBS for 1 h prior to addition of splenocytes. Immediately after their isolation, splenocytes were seeded onto the coated 96-well plate at a cell density of 1 × 10 6 cells per well in a final volume of 100 μL. The splenocyte cultures were incubated for 48 h at 37°C in a CO 2 (5%) incubator. Following incubation, each plate was washed 4× with PBS containing 0.05% Tween 20 for 2 min, followed by washing 2× with PBS for 2 min. 100 μL of horseradish peroxidase (HRP) conjugated antimouse IgG at a concentration of 1 μg/mL was added to each well and incubated for 1 h at 37°C. Following a second wash step, identical to previously described, a buffer containing TrueBlue Peroxidase Substrate (Kirkegaard & Perry Laboratories, Inc) and agarose (1:1 ratio) was heated in a water bath to 56°C and 100 μL was added to each well using reverse pipetting to avoid bubbles. Plates were incubated overnight at 4°C before reading on the CTL Ultimate S6 ImmunoSpot Analyzer (Cellular Technology Limited). Analysis of spots was done using CTL ImmunoSpot software (Cellular Technology Limited).
Statistical analysis
Statistical evaluation of data was performed using a one-way or twoway analysis of variance (ANOVA) as experimentally appropriate, followed by Tukey and Sidak multiple comparison tests. Trends were described following individual t-tests and linear regression analysis. A single outlier was removed from the cytokine analysis of the IFA with DEX and PLP group (Fig. 5) following outlier confirmation via the Grubb' Outlier Test. The criteria for statistical significance for all analyses was set at p < 0.05. The majority of analyses were performed using GraphPad Software (GraphPad Software Inc.) and linear regression analysis to determine data trends was performed using MATLAB (The MathWorks, Inc.).
Results
Characterization of IFA emulsion containing PLP and DEX
IFA oil was combined at a 1:1 ratio with phosphate buffered saline (PBS) using a micro-emulsifying needle to create an emulsion that was observed to be physically stable for upwards of 9 h (Supplemental Fig. 1 ). The emulsion was imaged using Nile Blue A as an oil-partitioning dye (Fig. 1) . The resulting Bright Field (Fig. 1A) , fluorescent (Fig. 1B) and composite (Fig. 1C) images depict aqueous droplets of PBS contained by an oil phase medium; confirming the water-in-oil structure of the emulsion. Droplet sizes reached diameters of up to 50 μm.
A 1:1 IFA oil: PBS emulsion was created containing PLP and DEX for the co-delivery of autoantigen and immunomodulator. The release of both PLP and DEX from either the IFA emulsion or PBS was measured by placing each formulation into a dialysis membrane (6000-8000 Da MWCO) and tracking the release into sink conditions of PBS at 37°C. PLP and DEX were found to be fully released from PBS within the membrane after 24 h and 10 h, respectively (Fig. 2) . DEX within the IFA emulsion was not fully released until approximately 120 h ( Fig. 2A) . PLP was much slower to release from the IFA emulsion, with < 10% of the total PLP in the formulation being released within 192 h (Fig. 2B) . Several additional emulsions with varying IFA oil to PBS ratios were tested in order to verify the presence and eventual release of PLP, revealing that decreasing oil content increased the release of PLP within 48 h (Supplemental Fig. 2 ).
Treatments containing PLP in IFA emulsion suppress EAE symptoms
IFA emulsion containing PLP and DEX, along with each combination of the components and a PBS control, were tested in mice induced with EAE. Treatments groups include PBS, IFA, DEX, PLP, IFA with DEX, IFA with PLP, DEX + PLP, and IFA with DEX + PLP. Treatments were given subcutaneously between the shoulder blades on days 4, 7, and 10 of the study (as shown on Figs. 3A-B and 4A-B) . By day 12, half of the mice in the PBS control group had died. Due to these deaths, and the corresponding disease score of 5, the PBS was statistically significant from all other treatments, including the IFA vehicle control, on at least one day of the study ( Fig. 3A-B) . Additionally, due to the high error in clinical score associated with the days on which the PBS mice died (days 11-12), the IFA group is shown as an alternative control compared to all other treatments (Fig. 3) . Weight changes were also monitored throughout the study and are shown as a percent change as compared to day 8, the last day with no disease symptoms (Fig. 4) . Although the death of the three PBS treated mice contributed to a significant increase in clinical score, the weight change was unaffected. In fact, there was no statistical difference between IFA and PBS treatment groups in terms of weight change (Fig. 4A) .
In determining the potential benefits offered by co-delivery of autoantigen and immunomodulator, IFA with DEX + PLP was also compared to the clinical score and change in weight from each treatment group (Figs. 3 and 4) . IFA with DEX + PLP significantly decreased clinical score and weight change as compared to PBS on three days of the study (Figs. 3B and 4B) . Additionally, as compared to IFA alone, IFA with DEX + PLP decreased both the clinical score and weight change during days before, during, and after peak disease (as determined by peak clinical scores and maximum weight change, see Supplemental Table 1 ) (Figs. 3C and 4C) . IFA with DEX + PLP also significantly suppressed disease symptoms on at least one day during the study as compared to DEX only, IFA with DEX, and DEX + PLP (Fig. 3D, F, H) . Treatments that were not statistically different than IFA with DEX + PLP; both PLP and IFA with PLP, did significantly decrease clinical scores as compared to IFA (Fig. 3E, G) . Several PLP-containing treatments (PLP, IFA with PLP, and IFA with DEX + PLP) also significantly decreased the peak clinical score as compared to the PBS control. Interestingly, both IFA with DEX + PLP and IFA with PLP suppressed EAE symptoms to a similar degree. The suppression by both treatments containing PLP in IFA is most clearly observed by examining the area under the curve for clinical score and peak clinical disease score (Supplemental Fig. 3) . Surprisingly, this same trend was not seen in weight change data, as IFA with PLP actually had significantly more weight loss as compared to IFA with DEX + PLP around the peak of disease (Fig. 4G ).
Dexamethasone shifts cytokine profiles away from inflammation
Following disease remission, on day 25 of the EAE study, splenocytes were collected from the mice and were rechallenged in vitro with and without PLP antigen. Cellular metabolic activity and cytokine responses were measured at 120 hour post antigen rechallenge (Fig. 5) . Metabolic activity as measured by resazurin was found to significantly increase with DEX treatment as compared to IFA, IFA with DEX, and IFA with DEX + PLP without rechallenge (Fig. 5A) . DEX treatment also increased metabolic activity both with and without rechallenge as compared to treatment with PLP (Fig. 5A) . Additionally, DEX + PLP was found to increase metabolic activity as compared to PLP with antigen rechallenge (Fig. 5A) .
Rechallenge with PLP was found to significantly increase the cytokine levels of GM-CSF, IFN-γ, TNF-α, IL-6, and IL-4 for the majority of treatment groups and increased levels of IL-10, IL-17, IL-23, and IL-15 in some of the treatment groups (Fig. 5 ). Significant differences between the treatment groups were found in the cytokine response of GM-CSF, IFN-γ, IL-6, IL-4, and IL-23; however, differences were only found for samples including PLP rechallenge. Treatments containing DEX tended to decrease pro-inflammatory cytokines including GM-CSF, IFN-γ, and IL-23 as compared to other treatment groups upon rechallenge with PLP (Fig. 5B, C, J) . Both treatments of IFA and PLP alone were found to significantly increase the pro-inflammatory GM-CSF as compared to IFA with DEX and IFA with DEX + PLP (Fig. 5B) . IL-23 also significantly increased due to treatment with PLP, this time compared to DEX, and IFA with DEX (Fig. 5J) . Surprisingly, the general pro-inflammatory cytokine IFN-γ was shown to increase with IFA with PLP following rechallenge, a treatment that was effective at suppressing clinical score in vivo. IFA with PLP significantly increased levels of IFN-γ as compared to treatments of IFA only, DEX + PLP, and IFA with DEX + PLP (Fig. 5C ). IL-6 was shown to be significantly increased with DEX treatment as compared to IFA with DEX and IFA with DEX + PLP (Fig. 5F ). Unlike the majority of cytokines analyzed, IL-4 significantly increased with PBS treatment as compared to all other treatment groups (Fig. 5I) .
Effective in vivo therapies increase B-cell-related responses in splenocytes
In addition to cytokine responses, changes in cell populations in the splenocytes obtained from the different in vivo treatment groups were examined both with and without PLP antigen rechallenge (Fig. 6 ). The population of T-cells, as identified by CD3, was found to be statistically similar for all treatment groups, both with and without rechallenge (Fig. 6A) . CD11c, which is a common marker for dendritic cells (DCs), was found to be increased both with and without antigen rechallenge for IFA with DEX + PLP and with antigen for IFA with PLP (Fig. 6B) . Bcells, as identified by CD19, were found to be significantly increased in the IFA with DEX + PLP treatment group (Fig. 6C, F) . CD19 + CD11c + cells were also analyzed, as these cells have been shown to act as autoimmune associated B-cells (ABCs) [38, 39] . The CD19 + CD11c + population was significantly increased for the IFA with DEX + PLP treatment group without antigen rechallenge (Fig. 6D) . The ABC population in the IFA with DEX + PLP group was significantly higher than all other treatment groups as a percent of the total splenocytes; however, the ABCs were not increased as a percentage of the B-cell (CD19 +) population (Fig. 6E) .
Autoantibody production was also measured using ELISpot to determine the number of cells producing PLP-specific antibodies in the spleen following each in vivo treatment. Similar to the increased presence of B-cells demonstrated by flow cytometry, ELISpot showed significantly higher anti-PLP antibody producing cells in splenocytes from mice treated by IFA with DEX + PLP as compared to other treatment groups (Fig. 7) . 
Discussion
The combination of autoantigen and immunomodulators has recently emerged as a potentially effective ASIT strategy for the treatment of autoimmunity [6] . In this study, IFA was investigated as a co-delivery vehicle in order to treat EAE with a combination of DEX and PLP. Our studies demonstrate that controlled release of DEX and PLP from IFA may assist in suppressing EAE. IFA has been previously indicated to have significant immunosuppressive properties alone [27] ; however, we did not observe this phenomenon. IFA suppressed disease symptoms as compared to the PBS control on only one day, which was the same as was seen for all other treatment groups (Fig. 3A) . When used as a delivery vehicle for autoantigen or immunomodulator, IFA containing PLP or DEX + PLP resulted in the most pronounced disease suppression ( Fig. 3 and Supplemental Fig. 3) .
The delivery of PLP appeared to play a major role in EAE disease suppression, such that co-delivery of DEX and PLP in IFA did not improve the suppression of disease clinical scores to any noticeable extent as compared to IFA with only PLP (Fig. 3G) . The importance of PLP in symptom suppression by an IFA formulation may be due to controlled release from aqueous droplets within the emulsion. In particular, the release of PLP into solution was greatly slowed when it was incorporated into IFA emulsions containing 1:1 ratios of oil to PBS (Fig. 2B and Supplemental Fig. 2) . The slow release of PLP from the IFA emulsion may be extending the exposure of autoantigen to antigenpresenting cells (APCs), allowing the therapy to influence the immune system long after the injection is administered. Previous studies in animal models of autoimmunity have seen similar phenomena, where the controlled release of autoantigen increases disease suppression both with and without an immunomodulatory signal [7, 8, 11, [40] [41] [42] ]. Another reason for the ability of PLP in IFA to suppress disease is the entrapment of the aqueous phase, containing the hydrophilic PLP, within the IFA oil matrix as visually demonstrated in Fig. 1 . Due to the low hydrophile-lipophile balance of mannide monooleate, the surfactant used in IFA, the propensity to create emulsions in which the water phase is entrapped in the oil is favored. The water-in-oil IFA emulsion structure with the entrapment of a hydrophilic antigen has been found to both protect the antigen from degradation and allow for a prolonged immune response [21] . The entrapment of PLP within water droplets of our IFA emulsion may contribute to antigen persistence at the injection site, and consequentially, improved uptake by APCs [43, 44] . The emulsion stability of up to 9 h (Supplemental Fig. 1 ) may also help prolong antigen presence at for enhanced APC uptake.
We also observed that treatments containing PLP, even without controlled release, significantly decreased peak clinical score and appeared to delay disease onset ( Fig. 3 and Supplemental Fig. 3 ). Treatment with an appropriate dose of autoantigen has often been reported to decrease autoimmune symptoms in animals, but has not been successfully translated to the clinic [3, 45] . The EAE in vivo efficacy of this treatment was also contradictory to the cytokine response observed in splenocytes obtained on day 25 of the study. Treating EAE mice with PLP alone was shown to promote pro-inflammatory cytokine production by significantly increasing GM-CSF and IL-23, and slightly increasing IFN-γ and IL-2 although not to a significant degree compared to other treatments (Fig. 5) . The correlation of poor efficacy of autoantigen alone in humans [3, 45] and the increased pro-inflammatory cytokine production by PLP treatment in EAE, as demonstrated in this manuscript, emphasizes the importance of analyzing the immune response in addition to clinical symptoms. The in vivo data indicated the importance of controlled release of autoantigen in the creation of effective ASIT, while the addition of an immunomodulator such as DEX had little effect on clinical symptoms (Figs. 3 and 4) . When analyzing the immune response more closely, it was found that DEX plays an important role in shifting the cytokine profile away from pro-inflammatory Th1/Th17 responses (Fig. 5) . Decreases in pro-inflammatory cytokine levels are in direct contrast with an increase in cellular metabolic activity upon DEX treatment, therefore the suppression of pro-inflammatory cytokine by DEX may be even more significant when considering the results on a per metabolizing cell basis (Fig. 5A) . DEX was also shown to increase IL-6 (Fig. 5F) ; however, this cytokine can be indicative of both pro-inflammatory (Th17) and regulatory (Treg) immune responses depending on the presence of other cytokine responses [46, 47] . The increase in IL-6 coupled with a decrease in IL-23 and GM-CSF, along with no change in IL-17, suggests that DEX is not producing a Th17 response and therefore IL-6 production may not be indicative of inflammation [46, 47] . Another cytokine demonstrating unexpected results was IL-4, which was shown to decrease with all therapies, even IFA alone (Fig. 5I) ; however, the role of IL-4 in the treatment of EAE has been debated [48] . Interesting immunological trends due to DEX treatment were also observed in the CD11c + dendritic cell (DC) population upon rechallenge with PLP (Fig. 6B) . IFA with DEX and IFA with DEX + PLP significantly increased the population of DCs compared to the majority of treatments, and DEX + PLP increased DCs as compared to PLP only treatment. The increase of DCs with treatments containing DEX is directly reverse of the trend for DEX to decrease GM-CSF (Fig. 5B) . GM-CSF has been known to be essential for the generation of inflammatory DCs from monocytes in the spleen, and plays a crucial role in EAE pathogenesis [49] . The inversely proportional trend of GM-CSF and CD11c + DCs following treatments with DEX may indicate that the DCs being produced are not pro-inflammatory, and may actually be immature or even tolerogenic [50, 51] . CD11c + DCs have been shown to act as tolerogenic DCs in the spleen [50] . Also, the treatment of DCs with DEX has previously been demonstrated to produce higher levels of tolerogenic DCs [49, [52] [53] [54] . Additionally, although not statistically significant, a slight trend in the decrease of CD3 + T-cells with the addition of DEX was also noted (Fig. 6A) .
Previous studies co-administering IFA and autoantigen have shown that a shift towards a Th2/humoral immune response allows for the suppression of Th1/Th17-mediated autoimmune diseases [19, 20] . Our study indicates an increased humoral response with both increased autoantibody production and B-cell populations in splenocytes from mice treated with either IFA with PLP or IFA with DEX + PLP (Figs. 6 and 7). Although IFA with DEX + PLP increases the percent of autoimmune associated B-cells (ABCs) in the entire splenocyte population, this trend seems to be associated with an increase in B-cells overall rather than an increase in the proportion of B-cells that are ABCs (Fig. 6D, E) . Both B-cell and ABC populations are found to significantly decrease upon rechallenge with antigen. Unresponsiveness to antigen rechallenge may indicate that many of these cells are anergic and therefore not contributing to EAE progression [55, 56] .
In measuring PLP-specific autoantibody producing B-cells via ELISpot, we discovered that the treatments that suppressed clinical symptoms of EAE had much higher levels of PLP-specific antibodies (Fig. 7) . Increased production of antibody following effective treatment with IFA and autoantigen has been observed before in both human autoimmunity and animal models [20, 30] . An increase in antibody production against autoantigen has been shown to correspond to skewing the immune response towards a Th2/humoral response resulting in suppression of Th1/Th17-mediated autoimmunity [20] . Our results demonstrating both an increase in the B-cell population and PLPspecific antibody production with IFA with DEX + PLP treatment of EAE support the hypothesis that the clinical disease suppression may be due to an increased Th2/humoral immune response.
Conclusions
As the combination of autoantigen and immunomodulator increases in popularity as an effective autoimmune therapeutic strategy, it is important to understand how each component contributes to the desired outcome. By investigating all possible treatment combinations of DEX and PLP using IFA as a delivery vehicle, we were able to identify important aspects of EAE treatment efficacy. Although co-delivery of DEX and PLP was hypothesized to be most effective, it was found that IFA with PLP was just as efficacious at ameliorating disease symptoms in vivo, indicating the importance of controlled delivery of autoantigen. Upon closer analysis of the immunological responses, it was found that DEX plays an important role in decreasing pro-inflammatory cytokines and possibly increasing tolerogenic DCs. Additionally, the co-delivery treatment of IFA with PLP and DEX was shown to increase B-cell populations and antibody production; demonstrating an increased humoral immune response as compared to controls. Overall, this data indicates that co-delivery of PLP autoantigen and DEX in an IFA emulsion is effective in the treatment of a murine autoimmune model.
